Last $12.17 USD
Change Today +0.305 / 2.57%
Volume 2.9M
As of 2:52 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

opko health inc (OPK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - $12.32
52 Week Low
02/5/14 - $7.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OPKO HEALTH INC (OPK)

opko health inc (OPK) Related Businessweek News

View More BusinessWeek News

opko health inc (OPK) Details

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company develops a range of solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals, and vaccines. Its product pipeline includes various pharmaceutical compounds and technologies in research and development for a range of indications and conditions. The company’s lead products comprise RayaldyTM, a vitamin D prohormone, which in phase III clinical development stage to treat secondary hyperparathyroidism in patients with stage III or IV chronic kidney disease and vitamin D insufficiency; and Alpharen, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. It also manufactures, sells, and licenses specialty active pharmaceutical ingredients for pharmaceutical companies. In addition, the company is involved in the discovery of new drugs for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and developing a protein-based influenza vaccine that would offer protection against influenza, as well as has various therapeutic agents for respiratory disorders in clinical development, including products for asthma, chronic obstructive pulmonary disease, and chronic cough. Further, it develops rolapitant, a potent and selective competitive antagonist that has completed phase II clinical testing for prevention of chemotherapy induced nausea and vomiting. It also operates OPKO Lab, a full-service medical laboratory specializing in urologic pathology. The company operates in the United States, Chile, Spain, Israel, Mexico, and Ireland. OPKO Health, Inc. is based in Miami, Florida.

625 Employees
Last Reported Date: 03/3/14

opko health inc (OPK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $492.3K
Vice Chairman and Chief Technical Officer
Total Annual Compensation: $482.3K
Executive Vice President of Administration an...
Total Annual Compensation: $455.0K
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

opko health inc (OPK) Key Developments

OPKO Launches the 4Kscore Test in Mexico

OPKO Health, Inc. announced the launch of the 4Kscore test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S. and European launch of the 4Kscore test in 2014. The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer. The test was developed and validated by OPKO in a 1,012 patient blinded, prospective study in the United States in 2014.

Opko Health, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 04:00 PM

Opko Health, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 04:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Phillip Frost, Chairman and Chief Executive Officer.

OPKO Health, Inc., OPKO Ireland Ltd. and Pfizer, Inc. Enter into Development, Commercialization License Agreement

On December 13, 2014, OPKO Health, Inc., OPKO Ireland Ltd. and Pfizer, Inc. entered into a Development, Commercialization License Agreement for the company’s long-acting human growth hormone product (hGH-CTP) for the treatment of growth hormone deficiency (GHD). Under the terms of the Agreement, the company granted to Pfizer an exclusive license under applicable patents, patent applications, and know-how owned by OPKO to develop, commercialize, and manufacture hGH-CTP. The company will receive an initial payment of $295 million within fifteen days of closing, a portion of which will be used by OPKO to fund research and development expenses. OPKO is also eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. Under the Agreement, the company is eligible to receive tiered, double digit royalty payments upon commencement of sales of hGH-CTP for adult GHD. Upon the approval and launch of hGH-CTP for pediatric GHD in certain major markets, the Agreement will convert into a regional tiered profit sharing arrangement covering sales of hGH-CTP and Pfizer’s Genotropin® for all indications in the applicable region. As part of the strategic collaboration, the companies will share responsibility for the conduct of trials specified within an agreed-upon global development plan, with each company leading certain activities within the plan. OPKO will lead the clinical activities and Pfizer will lead the manufacturing activities covered by the global development plan. Development activities under the global collaboration will be managed through a shared governance structure with both companies having equal representation on a joint steering committee. For the initial global development plan agreed to by the companies, OPKO will fund their development activities subject to an agreed upon cap. Costs in excess of the cap will be allocated between the parties in accordance with the Agreement. Pfizer will be responsible for all development costs for additional markets and indications that are not part of the development plan, as well as all post-marketing studies and commercialization activities. The Agreement will remain in effect until the last sale of the Licensed Product, unless earlier terminated as permitted under the Agreement. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Agreement is terminated by OPKO for Pfizer’s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to OPKO for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to OPKO in order to support continued development and commercialization of product.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OPK:US $12.17 USD +0.305

OPK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OPK.
View Industry Companies

Industry Analysis


Industry Average

Valuation OPK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.8x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 56.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPKO HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at